Visão geral da empresa
A biopharmaceutical entity, Xenetic Biosciences, Inc. is dedicated to advancing immune-oncology technologies specifically designed to treat various forms of cancer. The company's core operational focus involves the development and application of DNase technology, which functions by targeting neutrophil extracellular traps (NETs) that play a critical role in cancer growth, metastasis, and progression while also influencing immunotherapy and chemotherapy efficacy. Operating within the Healthcare sector as a Biotechnology company, the firm leverages specialized scientific expertise to address complex oncological challenges through proprietary biological mechanisms. Currently, the company employs a lean workforce of two individuals to execute its strategic initiatives, resulting in a total market capitalization of $6.99M and annual revenue of $2.98M. These valuation and revenue figures indicate that the company operates as a small-cap entity with limited historical sales volume, suggesting it is in an early-stage development phase where market penetration and commercialization scale are yet to be fully realized relative to larger established peers in the biotechnology industry.
Saúde financeira
The company reported revenue of $2.98M over the trailing twelve months, yet recorded a net income of -$2,680,860, revealing a significant structural gap where operating costs substantially exceed current revenue generation. This negative net income, coupled with an EBITDA that is not available due to the lack of profitability, underscores the typical burn rate associated with pre-revenue or early-revenue biotechnology firms investing heavily in research and development. The free cash flow stands at -$1,377,405, indicating that the company is consuming cash reserves to fund its operations and technological advancements rather than generating surplus liquidity for distribution. Despite these outflows, the balance sheet demonstrates a conservative capital structure with total cash holdings of $7.88M against zero total debt, providing a substantial buffer against operational deficits. The company maintains a current ratio of 8.32, which signals robust short-term liquidity and an ability to meet its financial obligations well beyond current requirements without immediate distress. Furthermore, the return on equity is recorded at -40.0% and the return on assets at -23.2%, metrics that reflect the dilutive effect of losses on shareholder value and asset efficiency typical of growth-stage biotech firms prioritizing R&D over immediate profitability.
Avaliação de valorização
Xenetic Biosciences, Inc. presents a trailing P/E ratio that is not available due to negative earnings, while the forward P/E is listed as -4.62, implying that future earnings expectations remain negative or that the stock is valued based on non-earnings multiples typical for loss-making biopharmaceutical companies. The price-to-book ratio is 0.95, suggesting that the market is valuing the company at approximately equal to its book value, which indicates no significant market premium is being assigned to its intangible assets or proprietary technology at this time. As an alternative valuation metric, the price-to-sales ratio stands at 2.35, while the EV/EBITDA is not available, collectively suggesting that investors are pricing the stock based on revenue multiples rather than earnings power or enterprise value efficiency. The stock has experienced significant volatility, trading between a 52-week low of $1.90 and a 52-week high of $13.93, meaning the current price sits somewhere within this wide range subject to market sentiment and liquidity conditions. With a beta of 2.21, the stock exhibits price volatility that is more than double that of the broader market, indicating high sensitivity to market movements and sector-specific risks for traders and risk-adjusted investors.
Growth & Income
The company achieved a revenue growth year-over-year of 18.1%, whereas the earnings growth year-over-year is not available due to the persistent net losses, implying that top-line expansion is outpacing the realization of profitability in the current fiscal cycle. As the company does not distribute dividends, the dividend yield is not available and the payout ratio is 0.0%, confirming that all generated cash and retained earnings are reinvested directly into research, development, and operational scaling rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the growth phase, where capital allocation focuses on advancing clinical trials and securing regulatory approvals to drive future commercial potential. Overall, the growth and income profile for Xenetic Biosciences, Inc. is characterized by strong top-line expansion supported by a debt-free balance sheet, though the absence of dividends and negative returns highlight the high-risk, high-reward nature of investing in early-stage immune-oncology biopharmaceutical companies.